Alexander Drilon
MD
Chief of Early Drug Development Service
👥Biography 个人简介
Alexander Drilon led pivotal trials of larotrectinib, entrectinib, selpercatinib, and repotrectinib across fusion-driven cancers, contributing to multiple tumor-agnostic FDA approvals in NTRK, RET, and ROS1 altered tumors. His work established fusion detection and targeting as a central axis of tumor-agnostic precision oncology. He continues to lead rare fusion drug development.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Alexander Drilon 的研究动态
Follow Alexander Drilon's research updates
留下邮箱，当我们发布与 Alexander Drilon（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment